echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Latest Phase III Study Data for Insomnia New Drug Daridorexant

    Latest Phase III Study Data for Insomnia New Drug Daridorexant

    • Last Update: 2020-07-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Insomnia is a symptom that does not go to sleep naturallyIt may be difficult to fall asleep (difficult to fall asleep) or it may be difficult to maintain a long period of deep sleep (difficult to maintain sleep)Insomnia is usually accompanied by symptoms such as daytime depression, drowsiness, irritability, or depressionpharmaceutical company Idorsia announced today that a Phase III study of daridorexant treating 924 adult and elderly insomniac patients showed that higher doses of the experimental bixin receptor antagonist daridorexant significantly improved sleep maintenance and total sleep timeThe company reported in April that daridorexant improved overall sleep and daytime performance when treating insomniaAlthough a 25-milligram dose of daridorexant reached the primary endpoint for improved sleep maintenance, the drug failed to significantly improve the persistent sleep incubation period (LPS)Guy Braunstein, head of global clinical development at Idorsia, said: "I am pleased to see the repeating role of 25 mg daridorexant in this large validation studyThe therapeutic effects of both studies were significant"The drugmaker said its goal is to submit regulatory documents for the compound to the Fdathe U.Saround the end of 2020
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.